A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 27, 2015

Primary Completion Date

March 13, 2017

Study Completion Date

March 13, 2017

Conditions

Solid TumorsOvarian Cancer

Interventions

DRUG

ALM201

Drug: ALM201 administered subcutaneously

Trial Locations (3)

Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast

Dept Medical Oncology, The Christie NHS Foundation Trust, Manchester

Freeman Hospital, Northern Centre for Cancer Care, Sir Bobby Robson Cancer Trial research Centre, Newcastle